Head to Head Contrast: Panbela Therapeutics (NASDAQ:PBLA) & Tango Therapeutics (NASDAQ:TNGX)

Panbela Therapeutics (NASDAQ:PBLA) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.

Institutional and Insider Ownership

4.4% of Panbela Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 0.0% of Panbela Therapeutics shares are held by company insiders. Comparatively, 6.2% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Panbela Therapeutics and Tango Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Panbela Therapeutics	0	1	1	0	2.50
Tango Therapeutics	0	0	7	1	3.13

Panbela Therapeutics currently has a consensus price target of $500.00, suggesting a potential upside of 146,958.82%. Tango Therapeutics has a consensus price target of $15.14, suggesting a potential upside of 82.44%. Given Panbela Therapeutics’ higher probable upside, analysts clearly believe Panbela Therapeutics is more favorable than Tango Therapeutics.

Profitability

This table compares Panbela Therapeutics and Tango Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Panbela Therapeutics	N/A	-70,194.55%	-269.84%
Tango Therapeutics	-274.04%	-44.73%	-28.79%

Volatility & Risk

Panbela Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

Valuation and Earnings

This table compares Panbela Therapeutics and Tango Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Panbela Therapeutics	N/A	N/A	-$25.26 million	($280.98)	0.00
Tango Therapeutics	$42.51 million	20.86	-$101.74 million	($1.13)	-7.35

Panbela Therapeutics has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Tango Therapeutics beats Panbela Therapeutics on 9 of the 14 factors compared between the two stocks.

About Panbela Therapeutics

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

About Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.